Aptinyx (Formerly Naurex/Allergan) uses a novel chemistry platform to discover small molecules for the treatment of a wide range of brain and CNS diseases, as well as psychiatric disorders.
NMDAR-An ion channel receptor activated by the neurotransmitter glutamate, implicated in regulating activity-dependent neural plasticity. Neural plasticity is important for cognitive functions such as learning and memory, as well as perception of pain. Aberrant neural plasticity has been linked to the development of various neurological disorders such as neuropathic pain, cognitive disorders, mood disorders and psychosis. Aptinyx uses a novel chemistry platform to discover small molecule modulators of NMDARs for the treatment of neurological disorders. The underlying technology of the platform has led to the development of two drug leads in late stage clinical trials with Allergan.
Towards the Molecular Foundations of Glutamatergic-targeted Antidepressants
Kroes, RA; Nilsson, CL. Current Opinions in Neuropharmacology. 2017; 15(1): 35-46.
Phase I: Parkinson’s Cognitive Impairment
Some molecules discovered with the Aptinyx platform are in phase III trials with Allergan.
- Small molecules
- Chemistry drug discovery platform
Aptinyx develops therapeutics in the following disease areas:
- Mood disorders
- Cognitive impairment (aging/disease)
- Pain disorders
No therapeutics are currently in preclinical development and thus Aptinyx may be interested in industry or academic partnerships for the preclinical development of new small molecule drug candidates.